After initially serving as a proving ground for integrating forward engineering principles into living cells, synthetic biology is making waves across diverse therapeutic areas. In this article, Dr. Dan Mandell, Co-Founder and CEO of GRO Biosciences, explains how the field is reshaping our understanding of the limits of cell- and molecular-based medicines.
George Church discusses the biotechnology underpinning GRO Biosciences Inc., which could provide a workaround for some well-known problems in protein therapeutics. The startup just hauled in millions to tackle those problems.
Beyond Meat (BYND) was one of last year’s hottest stocks. Shares of the plant-based meat company exploded 859% during its first three months out of the gate.
“DNA is like a computer program but far, far more advanced than any software ever created.”
Bill Gates wrote this in 1995, long before synthetic biology – a scientific discipline focused on reading, writing, and editing DNA – was being harnessed to program living cells.
By altering the genetic code in bacteria, researchers have demonstrated a method to make therapeutic proteins more stable, an advance that would improve the drugs’ effectiveness and convenience.
A year ago, a group of scientists convened in New York City to discuss an audacious plan: construct an entire human genome from scratch.
To uncover the mission of GRO Biosciences Inc., one has to look no further than its name. The acronym stands for “genomically recoded organisms”
Harvard geneticist and serial biotech entrepreneur George Church has co-founded a new startup that aims to develop “designer proteins” targeting a range of disorders.
GRO Biosciences Inc. wants to make a giant sector in the pharmaceutical industry even larger. The spinout from the lab of Harvard Medical School geneticist George Church aims to make protein drugs more versatile and effective
Biology is computation. It operates on the digital alphabet of biochemistry, which is quite a bit more complicated than binary, hex, or even Haskell.
BOSTON, November 3, 2021 – GRO Biosciences Inc. (“GRObio”), an emerging biotechnology company leveraging groundbreaking science to expand the amino acid alphabet and deliver on the promise of protein therapeutics, today announced the closing of a Series A financing